Home/Indications/Oncology/Ovarian Cancer

Ovarian Cancer

Oncology 5 original drugs

Novel Drugs

Reformulations

Drug Targets

Oncology indication. Ovarian Cancer has 5 FDA-approved novel treatments, led by VERASTEM INC, with 550 active industry clinical trials across 12 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Ovarian Cancer Market Leaders

Companies with the most FDA-approved novel Ovarian Cancer drugs.

Phase 3 Readouts Pro

12 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q3 2026

Olaparib

AstraZeneca

Estimated · fresh NCT04884360

Q3 2026

Avelumab

Pfizer

Estimated · fresh NCT05059522

Q4 2026

Plasmodium immunotherapy

CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.

Estimated · stale NCT05924776

Unlock 9 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Ovarian Cancer Treatments by Mechanism

Top 12 mechanisms across 46 industry trials with a known mechanism of action.

See full pipeline →

Poly(ADP-Ribose) Polymerase Inhibitor

11 trials 4 active 2 sponsors

Microtubule Inhibitor

8 trials 1 active 6 sponsors

Programmed Death Receptor-1 Blocking Antibody

7 trials 1 active 4 sponsors

Platinum-based Drug

5 trials 1 active 4 sponsors

Vascular Endothelial Growth Factor Inhibitor

4 trials 1 active 3 sponsors

Programmed Death Ligand-1 Blocker

3 trials 1 active 2 sponsors

DNA

2 trials 1 active 2 sponsors

ALK/ROS1/NTRK1/TRKB/TRKC

1 trials 1 active 1 sponsor

AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3

1 trials 1 active 1 sponsor

Kinase Inhibitor

2 trials 2 sponsors

PIK3CA

1 trials 1 sponsor

Alkylating Drug

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Ovarian Cancer Clinical Pipeline by Phase

648 industry-sponsored trials across 324 sponsors

View full landscape →

Showing 3 of 3 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
On Target Laboratories, LLC	CYTALUX (pafolacianine) injection	—	NOT YET RECRUITING	2026-11-30	NCT07469202
AstraZeneca	Olaparib	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	COMPLETED	2022-09-30	NCT04330040
AstraZeneca	Olaparib	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	COMPLETED	2020-04-17	NCT02476968

Showing 88 of 88 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
NX Development Corp	Gleolan	—	RECRUITING	2027-01	NCT05804370
Hansoh BioMedical R&D Company	HS-20089	—	RECRUITING	2027-03-07	NCT06855069
Jiangsu HengRui Medicine Co., Ltd.	SHR-A1811	—	RECRUITING	2027-05	NCT06828354
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1	—	RECRUITING	2027-06	NCT06994195
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc	Investigator's choice of Chemotherapy	—	RECRUITING	2028-05-31	NCT07546500
Genmab	Rina-S	—	RECRUITING	2028-10	NCT07225270
Verastem, Inc.	avutometinib	—	RECRUITING	2028-10-15	NCT06072781
Daiichi Sankyo	Trastuzumab Deruxtecan	—	RECRUITING	2028-11-01	NCT06819007
Incyte Corporation	INCB123667	—	RECRUITING	2028-11-15	NCT07214779
AstraZeneca	AZD5335	—	RECRUITING	2028-11-17	NCT07218809
Merck	Sacituzumab tirumotecan	—	RECRUITING	2029-04-27	NCT06824467
GE Healthcare	GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT)	—	RECRUITING	2029-06	NCT07219238
Imunon	IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)	—	RECRUITING	2032-10-31	NCT06915025
Merck	Sacituzumab tirumotecan	—	RECRUITING	2033-02-25	NCT07318558
Genelux Corporation	olvimulogene nanivacirepvec	—	RECRUITING	2026-06	NCT05281471
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-A1921	—	RECRUITING	2026-05-31	NCT06394492
Chipscreen Biosciences, Ltd.	chiauranib	—	RECRUITING	2024-12-31	NCT04921527
AstraZeneca	Olaparib	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2026-07-27	NCT04884360
CanariaBio Inc.	Oregovomab	—	ACTIVE NOT RECRUITING	2026-12-26	NCT04498117
Pfizer	Avelumab	Programmed Death Ligand-1 Blocker [EPC]	ACTIVE NOT RECRUITING	2026-12-31	NCT05059522
Genmab	Rina-S	—	ACTIVE NOT RECRUITING	2027-02	NCT06619236
AbbVie	Mirvetuximab soravtansine plus Bevacizumab	—	ACTIVE NOT RECRUITING	2027-04	NCT05445778
AstraZeneca	Olaparib	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-04-06	NCT04421963
Novita Pharmaceuticals, Inc.	NP-G2-044	—	ACTIVE NOT RECRUITING	2028-10-25	NCT07109414
BeiGene	Pamiparib capsule	—	ACTIVE NOT RECRUITING	2025-12-01	NCT03519230
AstraZeneca	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	ACTIVE NOT RECRUITING	2025-03-17	NCT03737643
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	ACTIVE NOT RECRUITING	2025-03-05	NCT05116189
Cordgenics, LLC	Standard Chemotherapy	—	ACTIVE NOT RECRUITING	2024-06-30	NCT03949283
pharmaand GmbH	Rucaparib	—	ACTIVE NOT RECRUITING	2024-05-20	NCT03522246
Impact Therapeutics, Inc.	IMP4927	—	ACTIVE NOT RECRUITING	2023-03-16	NCT04169997
AstraZeneca	Olaparib 300mg tablets	—	ACTIVE NOT RECRUITING	2018-05-17	NCT01844986
AstraZeneca	Olaparib 300mg tablets	—	ACTIVE NOT RECRUITING	2016-09-19	NCT01874353
CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.	Plasmodium immunotherapy	—	NOT YET RECRUITING	2026-11-30	NCT05924776
Jiangsu Alphamab Biopharmaceuticals Co., Ltd	JSKN003	—	NOT YET RECRUITING	2026-12-30	NCT06751485
Genmab	Rina-S	—	NOT YET RECRUITING	2027-09	NCT07604766
Sichuan Baili Pharmaceutical Co., Ltd.	BL-M07D1	—	NOT YET RECRUITING	2028-12	NCT07545460
Genmab	Rina-S	—	NOT YET RECRUITING	2029-12	NCT07564141
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-1921	—	NOT YET RECRUITING	2026-06-15	NCT06211023
Jina Pharmaceuticals Inc.	Paclitaxel Lipid Suspension	—	NOT YET RECRUITING	2025-12	NCT06867562
AGO Research GmbH	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	COMPLETED	2025-03-11	NCT03353831
AstraZeneca	Olaparib 300mg tablets	—	COMPLETED	2025-01-27	NCT03534453
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2024-08-26	NCT03740165
Jiangsu Simcere Pharmaceutical Co., Ltd.	BD0801	—	COMPLETED	2023-12-08	NCT04908787
NovoCure Ltd.	Paclitaxel	Microtubule Inhibitor [EPC]	COMPLETED	2023-05-18	NCT03940196
pharmaand GmbH	Rucaparib	—	COMPLETED	2023-03-08	NCT04676334
AbbVie	Mirvetuximab Soravtansine	—	COMPLETED	2023-03-06	NCT04209855
Vascular Biogenics Ltd. operating as VBL Therapeutics	VB-111 + Paclitaxel	—	COMPLETED	2022-07-19	NCT03398655
Roche	Paclitaxel	Microtubule Inhibitor [EPC]	COMPLETED	2022-02-08	NCT03038100
Jiangsu HengRui Medicine Co., Ltd.	Fluzoparib capsules	—	COMPLETED	2022-01-10	NCT03863860
ImmunoGen, Inc.	Mirvetuximab Soravtansine	—	COMPLETED	2021-11-16	NCT04296890
Roche	Paclitaxel	Microtubule Inhibitor [EPC]	COMPLETED	2021-05-26	NCT03635489
AstraZeneca	Active Comparator: Olaparib tablets	—	COMPLETED	2021-02-15	NCT03106987
AGO Research GmbH	Carboplatin	Platinum-based Drug [EPC]	COMPLETED	2021-01	NCT01837251
pharmaand GmbH	Chemotherapy	—	COMPLETED	2020-12-03	NCT02855944
AB Science	Masitinib	—	COMPLETED	2020-12	NCT02490488
AstraZeneca	Olaparib	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	COMPLETED	2020-10-02	NCT03402841
On Target Laboratories, LLC	OTL38	—	COMPLETED	2020-04-16	NCT03180307
ImmunoGen, Inc.	Mirvetuximab soravtansine	—	COMPLETED	2019-01	NCT02631876
PharmaMar	Lurbinectedin (PM01183)	—	COMPLETED	2018-10-12	NCT02421588
AstraZeneca	OLAPARIB	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	COMPLETED	2018-10-10	NCT02282020
Pfizer	avelumab	Programmed Death Ligand-1 Blocker [EPC]	COMPLETED	2018-09-19	NCT02580058
pharmaand GmbH	Rucaparib	—	COMPLETED	2017-04-01	NCT01968213
Tesaro, Inc.	Active comparator: Niraparib	—	COMPLETED	2016-04-22	NCT01847274
Roche	Paclitaxel	Microtubule Inhibitor [EPC]	COMPLETED	2015-03	NCT01239732
Roche	Gemcitabine (Chemotherapy)	—	COMPLETED	2015-01-30	NCT01684878
Roche	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	COMPLETED	2014-07-09	NCT00976911
Oasmia Pharmaceutical AB	Paclical®	—	COMPLETED	2013-10	NCT00989131
Amgen	AMG 386	—	COMPLETED	2013-03	NCT01204749
Novartis	Pazopanib	—	COMPLETED	2012-07-08	NCT00866697
Sutro Biopharma, Inc.	Luveltamab tazevibulin	—	TERMINATED	2025-08-26	NCT05870748
Mural Oncology, Inc	Nemvaleukin and Pembrolizumab Combination	—	TERMINATED	2025-01-08	NCT05092360
Mersana Therapeutics	Upifitimab rilsodotin	—	TERMINATED	2023-09-29	NCT05329545
Aravive, Inc.	Batiraxcept	—	TERMINATED	2023-08-04	NCT04729608
Novartis	Alpelisib	PIK3CA	TERMINATED	2023-04-21	NCT04729387
Pfizer	Chemotherapy + avelumab followed by avelumab + talazoparib	—	TERMINATED	2021-12-22	NCT03642132
AGO Research GmbH	Carboplatin	Platinum-based Drug [EPC]	TERMINATED	2021-03-03	NCT03690739
AbbVie	Veliparib	—	TERMINATED	2019-05-03	NCT02470585
Pfizer	carboplatin	Platinum-based Drug [EPC]	TERMINATED	2018-09-07	NCT02718417
Mateon Therapeutics	Fosbretabulin tromethamine	—	TERMINATED	2017-10	NCT02641639
Amgen	AMG 386	—	TERMINATED	2016-03	NCT01493505
Pfizer	MEK162, MEK inhibitor; oral	—	TERMINATED	2016-01-20	NCT01849874
Endocyte	EC145	—	TERMINATED	2015-05-31	NCT01170650
Amgen	AMG386 plus PLD	—	TERMINATED	2014-08-29	NCT01281254
Xian-Janssen Pharmaceutical Ltd.	CAELYX	—	TERMINATED	2014-05	NCT01840943
Morphotek	Farletuzumab	—	TERMINATED	2012-12-31	NCT00849667
SOTIO a.s.	DCVAC/OvCa	—	WITHDRAWN	2021-08	NCT03905902
Cordgenics, LLC	Chemotherapy	—	WITHDRAWN	2019-06-10	NCT03632798
AstraZeneca	OLAPARIB	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	WITHDRAWN	2019-06	NCT02392676

Showing 100 of 300 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Corcept Therapeutics	Relacorilant 150 mg once daily (QD)	—	RECRUITING	2026-08	NCT06906341
AtlasMedx, Incorporated	AMXI-5001:Dose Escalation Phase I	—	RECRUITING	2026-08	NCT04503265
Heronova Pharmaceuticals	DC05F01	—	RECRUITING	2026-08	NCT06873555
PMV Pharmaceuticals, Inc	rezatapopt	—	RECRUITING	2026-08-15	NCT04585750
858 Therapeutics, Inc.	ETX-19477	—	RECRUITING	2026-12	NCT06395519
Artios Pharma Ltd	ART0380	—	RECRUITING	2026-12	NCT04657068
InxMed (Shanghai) Co., Ltd.	IN10018	—	RECRUITING	2026-12-24	NCT06014528
Shanghai Jiaolian Drug Research and Development Co., Ltd	B013	—	RECRUITING	2026-12-31	NCT06434610
Shanghai Henlius Biotech	HLX43	—	RECRUITING	2026-12-31	NCT06769152
Evopoint Biosciences Inc.	XNW28012	—	RECRUITING	2026-12-31	NCT06799637
Jazz Pharmaceuticals	Zanidatamab	—	RECRUITING	2026-12-31	NCT06695845
BioInvent International AB	BI-1808	—	RECRUITING	2026-12-31	NCT04752826
Beijing Biotech	Dual-target CAR-NK cell product	—	RECRUITING	2027-02-17	NCT07480954
Compugen Ltd	COM701	—	RECRUITING	2027-03	NCT06888921
Allarity Therapeutics	2X-121	—	RECRUITING	2027-03	NCT03878849
Beijing Biotech	EB-DUALNK	—	RECRUITING	2027-03-14	NCT07589543
Regeneron	REGN5668	—	RECRUITING	2027-03-25	NCT04590326
Apollo Therapeutics Ltd	APL-5125	—	RECRUITING	2027-04	NCT06399757
Incyte Corporation	INCB123667	—	RECRUITING	2027-04-27	NCT07023627
ImmunityBio, Inc.	Gemcitabine	—	RECRUITING	2027-05	NCT06710288
Regeneron	Ubamatamab	—	RECRUITING	2027-05-10	NCT03564340
Beijing Biotech	Dual-target CAR-NK cell product	—	RECRUITING	2027-06-14	NCT07617753
Imunon	Paclitaxel	Microtubule Inhibitor [EPC]	RECRUITING	2027-06-30	NCT05739981
Genmab	Rina-S	—	RECRUITING	2027-07	NCT05579366
Incyclix Bio	INX-315	—	RECRUITING	2027-07	NCT05735080
MacroGenics	Lorigerlimab	—	RECRUITING	2027-07	NCT06730347
AstraZeneca	AZD8421	—	RECRUITING	2027-08-04	NCT06188520
Daiichi Sankyo	HER3-DXd	—	RECRUITING	2027-09-01	NCT06172478
AstraZeneca	AZD8205	—	RECRUITING	2027-09-29	NCT05123482
TORL Biotherapeutics, LLC	TORL-1-23	—	RECRUITING	2027-10	NCT06690775
Akeso	AK112 low dose	—	RECRUITING	2027-10	NCT06686030
AstraZeneca	Datopotamab deruxtecan (Dato-DXd)	—	RECRUITING	2027-10-01	NCT05489211
Filamon LTD	A novel hGIIA-Vimentin Inhibitor	—	RECRUITING	2027-10-26	NCT06926075
Radiopharm Theranostics, Ltd	177Lu-BetaBart	—	RECRUITING	2027-12	NCT07189871
Tubulis GmbH	TUB-040	—	RECRUITING	2027-12	NCT06303505
TORL Biotherapeutics, LLC	—	—	RECRUITING	2027-12	NCT07322094
Nanjing Leads Biolabs Co.,Ltd	LBL-024 for Injection	—	RECRUITING	2027-12-25	NCT07042802
AbbVie	IMGN151	—	RECRUITING	2028-01	NCT07024784
Jacobio Pharmaceuticals Co., Ltd.	JAB-8263	—	RECRUITING	2028-01	NCT04686682
AGO Research GmbH	olaparib	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	RECRUITING	2028-01	NCT04644289
AstraZeneca	Torvutatug samrotecan	—	RECRUITING	2028-01-06	NCT05797168
Perspective Therapeutics	[203Pb]Pb-PSV359	—	RECRUITING	2028-01-31	NCT06710756
Blue Earth Diagnostics	[18F]FPyQCP	—	RECRUITING	2028-01-31	NCT07432633
Avenzo Therapeutics, Inc.	AVZO-021	—	RECRUITING	2028-01-31	NCT05867251
Shenzhen Ionova Life Sciences Co., Ltd.	INV-6452	—	RECRUITING	2028-02-04	NCT07612891
Oncoinvent Solutions AS	Radspherin	—	RECRUITING	2028-02-29	NCT06504147
Theolytics Limited	THEO-260	—	RECRUITING	2028-06	NCT06618235
A2 Biotherapeutics Inc.	A2B694	—	RECRUITING	2028-06	NCT06051695
Tanabe Pharma America, Inc.	MT-4561	—	RECRUITING	2028-08	NCT06943521
Regeneron	Ubamatamab	—	RECRUITING	2028-10-30	NCT06787612
Acerand Therapeutics (Shanghai) Limited	ACE-86225106 tablet	—	RECRUITING	2028-12-21	NCT06380660
Terremoto Biosciences Inc.	TER-2013	—	RECRUITING	2028-12-30	NCT07109726
AbbVie	Mirvetuximab Soravtansine	—	RECRUITING	2029-01	NCT07059845
Merck	Raludotatug Deruxtecan	—	RECRUITING	2029-03-27	NCT06843447
Shenzhen Ionova Life Sciences Co., Ltd.	INV-8989	—	RECRUITING	2029-05	NCT07610798
AstraZeneca	AZD6750	—	RECRUITING	2029-10-02	NCT07115043
AbbVie	Carboplatin	Platinum-based Drug [EPC]	RECRUITING	2030-02	NCT06890338
AbbVie	Mirvetuximab Soravtansine	—	RECRUITING	2026-07	NCT06682988
Medicenna Therapeutics, Inc.	MDNA11	—	RECRUITING	2026-06-30	NCT05086692
Portage Biotech	TT-10	—	RECRUITING	2026-06-01	NCT04969315
AbbVie	Mirvetuximab Soravtansine	—	RECRUITING	2026-06	NCT06365853
InxMed (Shanghai) Co., Ltd.	IN10018 in combination with PLD	—	RECRUITING	2026-05-31	NCT05551507
Akeso	AK104	—	RECRUITING	2026-05-01	NCT06560112
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-A1811	—	RECRUITING	2026-05	NCT06840002
Innolake Biopharm	ILB-2109	—	RECRUITING	2026-01-25	NCT05955105
Hansoh BioMedical R&D Company	HS-20089	—	RECRUITING	2025-12-31	NCT06014190
GI Innovation, Inc.	GI-102 subcutaneous (SC)	—	RECRUITING	2025-11-12	NCT05824975
Cybrexa Therapeutics	CBX-12	—	RECRUITING	2025-10	NCT06315491
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	SSGJ-707	—	RECRUITING	2025-08	NCT06522828
Evopoint Biosciences Inc.	XNW27011	—	RECRUITING	2025-06-30	NCT06792435
BicycleTx Limited	BT5528	—	ACTIVE NOT RECRUITING	2026-07-31	NCT04180371
USWM CT, LLC	—	—	ACTIVE NOT RECRUITING	2026-08-12	NCT05601752
OncoC4, Inc.	ONC-392	—	ACTIVE NOT RECRUITING	2026-08-30	NCT05446298
CanariaBio Inc.	Oregovomab	—	ACTIVE NOT RECRUITING	2026-10-15	NCT05605535
AbbVie	Mirvetuximab soravtansine	—	ACTIVE NOT RECRUITING	2026-11	NCT05456685
CanariaBio Inc.	Oregovomab	—	ACTIVE NOT RECRUITING	2026-12-30	NCT05335993
Klus Pharma Inc.	SKB264	—	ACTIVE NOT RECRUITING	2026-12-31	NCT04152499
Pfizer	PF-07104091 monotherapy dose escalation	—	ACTIVE NOT RECRUITING	2026-12-31	NCT04553133
TILT Biotherapeutics Ltd.	TILT-123	—	ACTIVE NOT RECRUITING	2027-03	NCT05271318
Nuvation Bio Inc.	NUV-1511	—	ACTIVE NOT RECRUITING	2027-03	NCT06334432
AstraZeneca	AZD5305	—	ACTIVE NOT RECRUITING	2027-05-28	NCT04644068
Sensei Biotherapeutics, Inc.	SNS-101 (anti-VISTA)	—	ACTIVE NOT RECRUITING	2027-06	NCT05864144
Roche	Entrectinib	ALK/ROS1/NTRK1/TRKB/TRKC	ACTIVE NOT RECRUITING	2027-06-30	NCT02568267
Ascendis Pharma Oncology Division A/S	TransCon IL-2 β/γ	—	ACTIVE NOT RECRUITING	2027-08	NCT05081609
Roche	Ipatasertib	—	ACTIVE NOT RECRUITING	2028-02-28	NCT04931342
TCR2 Therapeutics	TC-510	—	ACTIVE NOT RECRUITING	2028-10-30	NCT05451849
Gradalis, Inc.	Vigil	—	ACTIVE NOT RECRUITING	2028-12	NCT02346747
OncoC4, Inc.	ONC-392	—	ACTIVE NOT RECRUITING	2026-06-30	NCT04140526
EMD Serono Research & Development Institute, Inc.	Tuvusertib (M1774)	—	ACTIVE NOT RECRUITING	2026-06-14	NCT06433219
Verastem, Inc.	Avutometinib (VS-6766) + Defactinib (VS-6063)	—	ACTIVE NOT RECRUITING	2025-12	NCT06682572
CanariaBio Inc.	Oregovomab	—	ACTIVE NOT RECRUITING	2025-10-30	NCT04938583
Salubris Biotherapeutics Inc	JK08	—	ACTIVE NOT RECRUITING	2025-10-17	NCT05620134
Xencor, Inc.	vudalimab	—	ACTIVE NOT RECRUITING	2025-10-15	NCT05032040
NextCure, Inc.	NC410	—	ACTIVE NOT RECRUITING	2025-07	NCT05572684
Takeda	TAK-853	—	ACTIVE NOT RECRUITING	2025-04-16	NCT06390995
23andMe, Inc.	23ME-00610	—	ACTIVE NOT RECRUITING	2025-03	NCT05199272
NGM Biopharmaceuticals, Inc	NGM707	—	ACTIVE NOT RECRUITING	2025-02	NCT04913337
TCR2 Therapeutics	gavo-cel	—	ACTIVE NOT RECRUITING	2024-11-19	NCT03907852
Verastem, Inc.	avutometinib (VS-6766)	—	ACTIVE NOT RECRUITING	2024-11-15	NCT04625270
Onconic Therapeutics Inc.	JPI-547	—	ACTIVE NOT RECRUITING	2024-11	NCT05475184

Showing 100 of 257 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
TORL Biotherapeutics, LLC	TORL-1-23	—	RECRUITING	2026-08-31	NCT05103683
Nurix Therapeutics, Inc.	NX-1607	—	RECRUITING	2026-08-31	NCT05107674
PhotonPharma, Inc.	Innocell Autologous Cellular Immunotherapy	—	RECRUITING	2026-11	NCT06366490
Mersana Therapeutics	XMT-1660	—	RECRUITING	2026-12	NCT05377996
NextCure, Inc.	LNCB74	—	RECRUITING	2026-12	NCT06774963
Context Therapeutics Inc.	CT-95	—	RECRUITING	2026-12	NCT06756035
Monopar Therapeutics	MNPR-101-PCTA-177Lu	—	RECRUITING	2026-12	NCT06617169
SystImmune Inc.	BL-B01D1	—	RECRUITING	2026-12-31	NCT05983432
Bicara Therapeutics	BCA101	—	RECRUITING	2026-12-31	NCT04429542
Chongqing Precision Biotech Co., Ltd	CD70 CAR-T cells	—	RECRUITING	2026-12-31	NCT06215950
Solve Therapeutics	SLV-154	—	RECRUITING	2027-01	NCT06771219
ViroMissile, Inc.	IDOV-Immune (oncolytic vaccinia virus)	—	RECRUITING	2027-01-31	NCT06910657
Daewoong Pharmaceutical Co. LTD.	DWZ2501 (Olaparib 150mg)	—	RECRUITING	2027-03	NCT07371104
Accent Therapeutics	ATX-295	—	RECRUITING	2027-04-30	NCT06799065
Eli Lilly	LY4052031	—	RECRUITING	2027-05	NCT06465069
Normunity AccelCo, Inc.	NRM-823	—	RECRUITING	2027-05-30	NCT07182149
OnCusp Therapeutics, Inc.	CUSP06	—	RECRUITING	2027-05-30	NCT06234423
Nerviano Medical Sciences	NMS-03305293	—	RECRUITING	2027-05-31	NCT06930755
AbbVie	Azirkitug	—	RECRUITING	2027-07	NCT05005403
Dren Bio	DR-0202	—	RECRUITING	2027-07	NCT06999187
IDEAYA Biosciences	IDE034	—	RECRUITING	2027-07-30	NCT07503808
Theolytics Limited	THEO-260	—	RECRUITING	2027-09	NCT07211659
AstraZeneca	AZD5335	—	RECRUITING	2027-10-15	NCT07402915
Verismo Therapeutics	SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR	—	RECRUITING	2027-12	NCT05568680
Xencor, Inc.	XmAb541	—	RECRUITING	2027-12	NCT06276491
Clasp Therapeutics, Inc.	CLSP-1025	—	RECRUITING	2027-12	NCT06778863
Ascentage Pharma Group Inc.	APG-2449	—	RECRUITING	2027-12	NCT03917043
Stemline Therapeutics, Inc.	MEN2501	—	RECRUITING	2027-12-02	NCT07226427
Nammi Therapeutics Inc	QXL138AM Injection every 2 weeks by IV Infusion	—	RECRUITING	2027-12-31	NCT06582017
Fate Therapeutics	FT836	—	RECRUITING	2028-01	NCT07216105
Whitehawk Therapeutics, Inc.	HWK-016, MUCIN-16-targeted ADC	—	RECRUITING	2028-02	NCT07470853
Chongqing Precision Biotech Co., Ltd	CD70-targeted CAR-T cells	—	RECRUITING	2028-03-31	NCT07181720
Regor Pharmaceuticals Inc.	RGT-490	—	RECRUITING	2028-04	NCT07524322
MacroGenics	MGC026 Dose Escalation	—	RECRUITING	2028-05	NCT06242470
Outpace Bio, Inc.	OPB-101	—	RECRUITING	2028-05-15	NCT07030907
Context Therapeutics Inc.	CTIM-76	—	RECRUITING	2028-05-31	NCT06515613
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc	Azenosertib	—	RECRUITING	2028-06-30	NCT04516447
ImmVirx Pty Ltd	IVX037	—	RECRUITING	2028-06-30	NCT05427487
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd	SYN818 and Olaparib will be administered	—	RECRUITING	2028-08-25	NCT07156253
Whitehawk Therapeutics, Inc.	HWK-007	—	RECRUITING	2028-10	NCT07444814
Zelluna Immunotherapy AS	ZI-MA4-1 (TCR-NK cells)	—	RECRUITING	2028-12	NCT07613723
Bristol-Myers Squibb	BMS-986500	—	RECRUITING	2028-12-14	NCT06997029
SystImmune Inc.	BL-M07D1	—	RECRUITING	2028-12-15	NCT06293898
Bristol-Myers Squibb	BMS-986463	—	RECRUITING	2028-12-19	NCT06476808
NiKang Therapeutics, Inc.	NKT3964	—	RECRUITING	2029-01	NCT06586957
AbbVie	ABBV-901	—	RECRUITING	2029-01	NCT07278336
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	EXS74539	—	RECRUITING	2029-03	NCT07517198
Epitopea Ltd	CryptiVax-1001	—	RECRUITING	2029-03	NCT07665515
Pheast Therapeutics	PHST001	—	RECRUITING	2029-04	NCT06840886
AstraZeneca	Autologous, engineered T Cells targeting TP53 R175H	—	RECRUITING	2029-07-31	NCT05877599
Boehringer Ingelheim	BI 3820768	—	RECRUITING	2029-09-07	NCT07306559
Conjupro Biotherapeutics, Inc.	SYS6043	—	RECRUITING	2029-12	NCT07424547
Regeneron	Cemiplimab	—	RECRUITING	2030-05-27	NCT06469281
Epsilogen Ltd	MOv18 IgE	—	RECRUITING	2026-07	NCT06547840
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd	SYN818	—	RECRUITING	2026-06-30	NCT06666270
Avacta Life Sciences Ltd	AVA6000	—	RECRUITING	2026-06-15	NCT04969835
Light Chain Bioscience - Novimmune SA	Biological NI-1801	—	RECRUITING	2026-05-30	NCT05403554
Boryung Pharmaceutical Co., Ltd	Olaparib 150 MG	—	RECRUITING	2026-05-15	NCT07069335
Jiangsu Hansoh Pharmaceutical Co., Ltd.	HS-10502 + NHA	—	RECRUITING	2026-05-07	NCT06769425
Radiopharm Theranostics, Ltd	RAD301 ([68Ga]-RAD301)	—	RECRUITING	2026-05	NCT05799274
Ascentage Pharma Group Inc.	APG -2449	—	RECRUITING	2026-05	NCT06687070
Jiangsu Hansoh Pharmaceutical Co., Ltd.	HS-10502	—	RECRUITING	2026-04-01	NCT05740956
Monopar Therapeutics	MNPR-101-DFO*-89Zr	—	RECRUITING	2026-04	NCT06337084
Shanghai Best-Link Bioscience, LLC	BL0175	—	RECRUITING	2026-02-20	NCT06738966
Chongqing Precision Biotech Co., Ltd	CD70 CAR-T cells	—	RECRUITING	2025-12-31	NCT06010875
Molecure S.A.	OATD-02	—	RECRUITING	2025-12	NCT05759923
Oxford Vacmedix UK Ltd.	OVM-200	—	RECRUITING	2025-11-30	NCT05104515
BioEclipse Therapeutics	CRX100 suspension for infusion	—	RECRUITING	2025-08	NCT04282044
BeiGene	BG-68501	—	ACTIVE NOT RECRUITING	2026-08-31	NCT06257264
IDEAYA Biosciences	IDE-161	—	ACTIVE NOT RECRUITING	2026-10	NCT05787587
USWM CT, LLC	—	—	ACTIVE NOT RECRUITING	2026-12-23	NCT04044859
TScan Therapeutics, Inc.	TSC-204-A0201	—	ACTIVE NOT RECRUITING	2026-12-30	NCT05973487
Eli Lilly	LY4101174	—	ACTIVE NOT RECRUITING	2027-03	NCT06238479
NeoTX Therapeutics Ltd.	—	—	ACTIVE NOT RECRUITING	2027-03-01	NCT03983954
MOMA Therapeutics	MOMA-313	—	ACTIVE NOT RECRUITING	2027-05-31	NCT06545942
Arcus Biosciences, Inc.	AB598	—	ACTIVE NOT RECRUITING	2027-09	NCT05891171
SystImmune Inc.	BL-M17D1	—	ACTIVE NOT RECRUITING	2027-09-01	NCT06714617
Atavistik Bio, Inc	ATV-1601	—	ACTIVE NOT RECRUITING	2028-08-31	NCT07038369
AbbVie	ABBV-400	—	ACTIVE NOT RECRUITING	2026-07	NCT06084481
Toray Industries, Inc	TRK-950	—	ACTIVE NOT RECRUITING	2026-06	NCT03872947
Poseida Therapeutics, Inc.	P-MUC1C-ALLO1 CAR-T cells	—	ACTIVE NOT RECRUITING	2026-04	NCT05239143
Nuvectis Pharma, Inc.	NXP800	—	ACTIVE NOT RECRUITING	2025-12	NCT05226507
Theratechnologies	TH1902	—	ACTIVE NOT RECRUITING	2025-12	NCT04706962
NGM Biopharmaceuticals, Inc	NGM831	—	ACTIVE NOT RECRUITING	2025-07	NCT05215574
AstraZeneca	Administration of ceralasertib	—	ACTIVE NOT RECRUITING	2025-03-04	NCT02264678
Agenus Inc.	Botensilimab	—	ACTIVE NOT RECRUITING	2025-01-13	NCT03860272
Precigen, Inc	PRGN-3005 UltraCAR-T cells	—	ACTIVE NOT RECRUITING	2024-12-15	NCT03907527
Shanghai PerHum Therapeutics Co., Ltd.	CCT303-406	—	ACTIVE NOT RECRUITING	2024-10-24	NCT04511871
Exelixis	cabozantinib	AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3	ACTIVE NOT RECRUITING	2023-02-21	NCT03170960
USWM CT, LLC	—	—	ACTIVE NOT RECRUITING	2022-12-27	NCT03132922
WestVac Biopharma Co., Ltd.	WSK-IM02	—	NOT YET RECRUITING	2027-03-31	NCT07462468
Chong Kun Dang Pharmaceutical	CKD-215	—	NOT YET RECRUITING	2027-06	NCT07532148
Medigene AG	Lymphodepletion	—	NOT YET RECRUITING	2027-12-01	NCT06748872
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd	SYN608	—	NOT YET RECRUITING	2028-07-31	NCT07088588
Xencor, Inc.	XmAb541	—	NOT YET RECRUITING	2028-12	NCT07593092
Outpace Bio, Inc.	OPB-201	—	NOT YET RECRUITING	2030-06	NCT07664735
Aromics Therapeutics	AROG4-01	—	NOT YET RECRUITING	2025-12	NCT06652529
Compugen Ltd	Dose escalation: COM902 monotherapy.	—	COMPLETED	2026-04-01	NCT04354246
SN BioScience	SNB-101	—	COMPLETED	2026-01-05	NCT04640480
Oncoinvent Solutions AS	Radspherin	—	COMPLETED	2025-09-30	NCT03732768

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Ovarian Cancer

VEGF (17) EGFR- (8) dMMR (4) HER2+ (3) HER2- (2) PD-L1 TPS ≥1% (1)

Novel Ovarian Cancer Drugs by Company (New molecular entities)

5 companies have an FDA-approved novel drug for Ovarian Cancer.

VERASTEM INC 1 drug

AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)

AVUTOMETINIB POTASSIUM

NDA 2025

ON TARGET LABS 1 drug

GSK 1 drug

Merck 1 drug

PHARMAAND 1 drug

Reformulations (2 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

Ovarian Cancer Drug Targets

Molecular targets of approved and investigational Ovarian Cancer drugs — 12 targets tracked.

VEGFA 5 PARP-1 2 PARP-2 2 Ribonucleotide reductase 1 PARP1 1 PARP2 1 PARP3 1 FAK 1 MAP2K1 1 Pyk2 1 PDCD1 1 PARP-3 1

Biosimilars (6 BLA approved) Click to expand

Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.

BIO-THERA SOLUTIONS LTD